Aktieanalys

Nanologica Q1 2024: Mixed start of the year - Redeye

{newsItem.title}

Redeye Publicerad: 29 Apr 2024 09:29

Redeye returns with an updated view on Nanologica following its Q1 report. Sales and EBIT was softer than our estimates, but the company reported its highest quarterly chromatography sales to date. We somewhat lower our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1000187/nanologica-q1-2024-mixed-start-of-the-year?utm_source=finwire&utm_medium=RSS

Nyheter om Nanologica

Läses av andra just nu

Om aktien Nanologica

Senaste nytt